European Archives - Page 1075 of 1159 - European Medical Journal

EMJ

ECC 2015: Cancer healthcare inequalities between and within countries in Europe

There is a growing divide in cancer healthcare and survivorship between populations across Europe. European Cancer Patient Coalition (ECPC), the largest…

EMJ

TAILORx: Prospective phase 3 trial validating a 21-gene expression assay in breast cancer

At the European Cancer Congress (ECC) 2015, Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, discusses the low-risk…

EMJ

ECC 2015: Challenging the European disparities in cancer care

European Cancer Patient Coalition (ECPC), the largest European cancer patients’ umbrella organisation, presented the paper, ‘Europe of Disparities in…

EMJ

ECC 2015: Hormonal therapy may prevent ovarian failure and preserve fertility in breast cancer

A meta-analysis was conducted to include 12 randomised trials and a total of 1,231 breast cancer patients receiving chemotherapy, with or without…

EMJ

Clinical access to genomic information in Europe

Genomic interventions may improve disease-risk stratification and patient-tailored treatment. At the European Cancer Congress (ECC) 2015, John Crown, MD…

EMJ

Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx)

At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincent’s University Hospital, Dublin, Ireland, discusses the low-risk registry…

EMJ

Phase 1b trial of avelumab in advanced gastric or gastroesophageal junction cancer

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a phase 1b…

EMJ

ECC 2015: Post-diagnosis aspirin improves survival in gastrointestinal cancers

Results from a study in The Netherlands involving 13,715 patients showed that aspirin use after a cancer diagnosis significantly improved overall…

EMJ

ECC 2015: New survival data from Combi-v trial of combination of two targeted therapies in melanoma

Updated results from the phase 3 COMBI-v trial of a combination of dabrafenib and trametinib for the first-line treatment of patients with…

EMJ

ECC 2015: NETTER-1 trial showed rare cancer responded unusually well to new treatment

NETTER-1, a phase 3 clinical trial, evaluated Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in patients with Grade 1–2 metastatic…